The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's method-of-use patents on Evista (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct. These patents provide protection for Evista through March of 2014.
The details can be read here.
No comments:
Post a Comment